MediWound Ltd (MDWD) is scheduled to announce Q1 2022 earnings on Tuesday, 17 May 2022, before market open. Wallstreet estimates an EPS of $-0.09 and a revenue of $4.29 M in the upcoming results. MediWound Ltd historically beated the wallstreet estimates 45% of the times.
About MediWound Ltd
MediWound Ltd. is a biopharmaceutical company that engages in the development, manufacture, and commercialize novel products to address unmet needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders. Its medicinal product, NexoBrid, is used to remove eschar in adults patients with deep partial- and full-thickness thermal burns. The company was founded by Lior Rosenberg and Marian Gorecki on January 27, 2000 and is headquartered in Yavne, Israel.